Recent Alzheimer's research has led to FDA-approved treatments that slow cognitive decline, such as Lecanemab and Donanemab. New diagnostic tools like PET scans and blood biomarker tests allow for ...

Space, An Early Frontier. When a brain region is tau-negative by SUVR (green arrow, left), spatial extent (dark blue) correlates better with measures of disease severity than does SUVR (light blue).

That involves a PET scan for diagnosis ... would have to be a sea-change in the clinical pathway to diagnosis if donanemab or Leqembi were to be available as routine therapy.

Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch ... as well as the required PET scans, are already covered under Medicare.

Then came positron emission tomography (PET) scans, which light up the proteins ... this potential benefit,” says Dr. Chin.

PET imaging analysis showed that ... the short-term efficacy-risk balance of donanemab and consider increasing MRI monitoring frequency during pretreatment and early treatment phases (e.g., baseline ...

Patients from the LUCIDITY trial who had received 16mg/day LMTX for 18 months were closely matched to subjects in the CPAD database on measures including age, sex, smoking history, APOE genotype, ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with ...

The University of Washington’s Memory and Brain Wellness Center at Harborview Medical Center has begun treating patients with donanemab ... specialized brain scans or tests of spinal fluid ...